Biohaven Gains After New Data From Epilepsy-Treatment Studies

Dow Jones05-27

By Christopher Kuo

Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy.

The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date.

The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy.

The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group.

The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline.

Biohaven said it is on track to announce the top-line results from first of the two Phase 2/3 studies in the second half of 2026.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 26, 2026 12:39 ET (16:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638954994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 00:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638954994","market":"us","top_or_hot":-1,"title":"Biohaven Gains After New Data From Epilepsy-Treatment Studies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy. \n</p>\n<p>\n  The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date. \n</p>\n<p>\n  The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy. \n</p>\n<p>\n  The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group. \n</p>\n<p>\n  The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline. \n</p>\n<p>\n  Biohaven said it is on track to announce the top-line results from first of the two Phase 2/3 studies in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 26, 2026 12:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Gains After New Data From Epilepsy-Treatment Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Gains After New Data From Epilepsy-Treatment Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-27 00:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy. \n</p>\n<p>\n  The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date. \n</p>\n<p>\n  The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy. \n</p>\n<p>\n  The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group. \n</p>\n<p>\n  The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline. \n</p>\n<p>\n  Biohaven said it is on track to announce the top-line results from first of the two Phase 2/3 studies in the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 26, 2026 12:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2638954994","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638954994","pubTimestamp":1779813540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy.The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date.The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy.The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group.The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline.Biohaven said it is on track to announce the top-line results from first of the two Phase 2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4139":"生物科技","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"癫痫治疗研究获得新数据后，Biohaven股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of Biohaven advanced after the biopharmaceutical company reported new data from studies of its treatment for focal epilepsy. \n\n\n  The stock rose 7.4%, to $10.15, midday Tuesday, but are still down 10% year to date. \n\n\n  The company's studies involve Opakalim, a drug that acts as a selective activator of Kv7.2/7.3 potassium channels in the brain to prevent seizures. The drug is currently in Phase 2/3 studies for the treatment of focal epilepsy. \n\n\n  The company said a randomized, double-blind clinical trial showed that subjects who took opakalim had a longer time before experiencing a second day with a generalized tonic-clonic seizure, compared with the placebo group. \n\n\n  The company also said a continuing open-label extension study in focal epilepsy showed 54% of patients with focal epilepsy on opakalim showed a more than 50% reduction in seizure frequency over six months of treatment compared with the baseline. \n\n\n  Biohaven said it is on track to announce the top-line results from first of the two Phase 2/3 studies in the second half of 2026. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 12:39 ET (16:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638954994","isCrawlerRequest":true}